| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6d40e044398947e5899630aa24f6402 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04 |
| filingDate |
2020-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62a4c8b4ad4a19ff234082f0d2ae507a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29f6d20671831fad3e66fb646fdbd949
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6afd244fadcfde3d9f003b74d77a2f4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5dac99185f973ae20972c2ff33036b9f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9612495d779246cc4f19ef42fff18c95 |
| publicationDate |
2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021013070-A1 |
| titleOfInvention |
Chimeric human papillomavirus 35 type l1 protein |
| abstract |
The present invention provides chimeric human papillomavirus 35 type L1 protein and polynucleotides encoding the same, and further provides HPV 35 type virus-like particles and a preparation method thereof. The chimeric human papillomavirus 35 type L1 protein comprises an N-terminal fragment derived from HPV 35 type L1 protein, the N-terminal fragment maintains immunogenicity of the HPV 35 type L1 protein; and a C-terminal fragment derived from a second type papillomavirus L1 protein, the second type papillomavirus L1 protein has better expression and solubility characteristics than other types of L1 protein; wherein the chimeric HPV35 type L1 protein has the immunogenicity of HPV 35 type L1 protein. The chimeric human papillomavirus 35 type L1 protein has higher expression and solubility, and can be used for mass production of vaccines. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022152204-A1 |
| priorityDate |
2019-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |